Dr Kate Hilyard is Chief Operating Officer at Healx, a technology company from Cambridge University focused on accelerating rare disease treatments by redesigning drug discovery. Healx integrates AI, deep pharmacology expertise, and patient engagement to intelligently match treatments to disease patients.
Kate has over 25 years experience in drug discovery working in the pharmaceutical, biotechnology and CRO industries. She has a track record of clear leadership building an integrated world-leading drug discovery organisation with a reputation for quality and delivery, using strong scientific, financial and commercial acumen to ensure a profitable and sustainable business generating growth in value to shareholders. Throughout her career, she has been driven to make a difference to patient lives, from her early academic research in human biology at Oxford and Harvard Universities, to leading drug discovery teams and, ultimately, to leading organisations whose mission is to discover drugs through a sustainable business model.
At Healx Kate will be leading the strategy implementation and growth to enable Healx to be able to deliver rare disease treatments at scale.
Do you want to write for us? Click here to find out how
Telling the truth about SME life today
Real Business has championed entrepreneurship in the UK since 1997. It is now the main source of inspiration, education, and collaboration for the owners of fast-growing businesses, from startups to mid-market companies. Real Business provides readers with high profile interviews, news, insight and industry benchmark reports, as well as a growing stable of events tailored to SME growth.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.